Actinium Pharmaceuticals, Inc.
AMEX:ATNM
4.27 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Actinium Pharmaceuticals, Inc. |
Symbool | ATNM |
Munteenheid | USD |
Prijs | 4.49 |
Beurswaarde | 121,219,224 |
Dividendpercentage | 0% |
52-weken bereik | 4.3 - 14.7 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sandesh C. Seth M.B.A., M.S., MBA |
Website | https://www.actiniumpharma.com |
An error occurred while fetching data.
Over Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)